Cancer Genetics, Beth Israel Deaconess to Study Genomic Markers for Non-Hodgkin Lymphoma Outcomes | GenomeWeb

NEW YORK (GenomeWeb) – Cancer Genetics and Beth Israel Deaconess Medical Center have partnered to study genomic biomarkers in non-Hodgkin lymphoma patients and correlate those markers with clinical outcomes, CGI said today.

CGI said the collaborators will correlate markers to treatment outcomes in around 200 patients with diffuse large B-cell lymphoma (DLBCL), the most common type of non-Hodgkin lymphoma. The company will incorporate any new markers validated in the study into a test to predict treatment outcomes for DLBCL patients.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.